Q-omics provides the consensus-scored AMDHD2 profile across patient tissues and cancer cell-line models. AMDHD2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, AMDHD2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, AMDHD2 protein abundance shows 21,784 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, KIRC, and BRCA as cancer lineages where AMDHD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMDHD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMDHD2 survival associations across molecular data types. AMDHD2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMDHD2 RNA expression–survival associations across cancer types. High AMDHD2 expression shows unfavorable associations in UVM, LUSC, COAD and LIHC, but favorable associations in CESC and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for AMDHD2 RNA expression.
This table summarizes AMDHD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for AMDHD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMDHD2 shows higher tumor expression in KIRC, HNSC, COAD, LIHC, STAD and BRCA. The KIRC box plot shows higher AMDHD2 RNA expression in tumor versus normal tissue (log2 FC = +0.879, t-test p < 0.001).
This table shows molecular features associated with AMDHD2 in patient tissues and cancer cell lines. In patient samples, AMDHD2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, AMDHD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
